Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase-Deficient Renal Cell Carcinoma.
Zacharias NM, Ozambela M, Karki M, He R, Chauhan PK, Pesquera PI, Hernandez Gonzalez AE, Ochoa O, Pieretti A, Chen H, De La Cerda C, Yu Z, Grover A, Hicks-Peňa S, Fowlkes NW, Wang L, Maity T, Rao P, Genovese G, Tannir NM, Karam JA, Msaouel P.
Zacharias NM, et al. Among authors: de la cerda c.
Mol Cancer Ther. 2025 Nov 3;24(11):1722-1732. doi: 10.1158/1535-7163.MCT-24-0703.
Mol Cancer Ther. 2025.
PMID: 40601845
Free PMC article.